Niramai vs Tempus

Tempus has a disclosed valuation of $8.1B, while Niramai's valuation is not publicly available, making a direct size comparison difficult. Tempus employs 2500 people.

Tempus has raised more in total funding at $1.1B, compared to Niramai's $17M — a gap of $1B. Combined, the two companies have completed 8 known funding rounds.

Tempus leads with an Awaira Score of 84/100, while Niramai sits at 60/100. That 24-point gap reflects real differences in funding, scale, and traction — it's not a vanity metric.

Niramai was founded by Geetha Manjunath in 2016. Tempus was founded by Eric Lefkofsky in 2015. Visit each company's profile on Awaira for a full founder biography.

Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare development and a major Indian public health challenge. Tempus: Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial intelligence to match patient-specific tumor characteristics with optimal therapeutic options, enabling oncologists to make data-informed treatment decisions. The company operates primarily in the United States and serves hospitals, health systems, and oncology practices through its cloud-based platform. Its applications span multiple cancer types including lung, colorectal, breast, and ovarian cancers. Tempus has secured $1.3 billion in total funding and achieved a valuation of $8.1 billion, reflecting significant investor confidence in precision oncology. The company went public, transitioning from private to public markets. Tempus competes with other AI health platforms and precision medicine companies like Foundation Medicine and others focused on genomic analysis and treatment selection. The company's growth trajectory reflects expanding adoption of AI-driven oncology tools and increasing demand for personalized cancer treatment protocols. Its competitive positioning centers on its data infrastructure scale and machine learning capabilities applied to complex clinical decision-making. Tempus combines clinical, imaging, and molecular data through AI to provide real-time oncology treatment recommendations at scale across U.S. health systems.

Tempus got there first, launching in 2015 — that's 1 year of extra runway. Niramai didn't arrive until 2016. In AI, that kind of head start means more training data, deeper customer relationships, and a bigger talent moat.

Niramai has about 50-200 employees; Tempus has about 2500. A bigger team usually means more revenue or heavier VC backing, but in AI, small teams can build at massive scale.

Yes — they're direct rivals. Both Niramai and Tempus compete in AI Healthcare, targeting many of the same buyers. If you're evaluating one, you should be looking at the other.